Cited by 662Alzheimer's disease research and treatmentsDrug Transport and Resistance MechanismsBarrier Structure and Function Studies

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer disease mouse model

Open access

Cirrito, J. R.·2005·Journal of Clinical Investigation

DOI 10.1172/jci25247PMC PMC1257538

Open this paper in CoChat — free account Open PDF

Abstract

Accumulation of amyloid-beta (Abeta) within extracellular spaces of the brain is a hallmark of Alzheimer disease (AD). In sporadic, late-onset AD, there is little evidence for increased Abeta production, suggesting that decreased elimination from the brain may contribute to elevated levels of Abeta and plaque formation. Efflux transport of Abeta across the blood-brain barrier (BBB) contributes to Abeta removal from the brain. P-glycoprotein (Pgp) is highly expressed on the luminal surface of brain capillary endothelial cells and contributes to the BBB. In Pgp-null mice, we show that [I]Abeta40 and [I]Abeta42 microinjected into the CNS clear at half the rate that they do in WT mice. When amyloid precursor protein-transgenic (APP-transgenic) mice were administered a Pgp inhibitor, Abeta levels within the brain interstitial fluid significantly increased within hours of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Abeta and enhanced Abeta deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and Abeta metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as provide a novel diagnostic and therapeutic target.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci25247

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I. H., & Gottesman, M. M. (1999) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 907
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830

Show all 34 references

Sorted by citations

Items 401–500 of 662

Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease
Robinson, M. J., Lee, B. Y., & Leonenko, Z. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.3.332 · Cited by 24
Single Photon Emission Computed Tomography and Positron Emission Tomography Imaging of Multi-drug Resistant P-glycoprotein—Monitoring a Transport Activity Important in Cancer, Blood–Brain Barrier Function and Alzheimer's Disease
Piwnica-Worms, D. R., Kesarwala, A. H., Pichler, A., Prior, J. L., & Sharma, V. (2006) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2006.06.007 · Cited by 21
Neurovascular Alterations in Alzheimer’s Disease: Transporter Expression Profiles and CNS Drug Access
McInerney, M. P., Short, J. L., & Nicolazzo, J. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0077-5 · Cited by 20
Rhythms in barriers and fluids: Circadian clock regulation in the aging neurovascular unit
Skapetze, L., Owino, S., Lo, E. H., Arai, K., Merrow, M. W., & Harrington, M. E. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106120 · Cited by 20
Neuroprotective effects of mesenchymal stromal cells in mouse models of Alzheimer’s Disease: The Mediating role of gut microbes and their metabolites via the Microbiome-Gut-Brain axis
Xing, C., Zhang, X., Wang, D., Chen, H., Gao, X., Sun, C., Guo, W., Roshan, S., Li, Y., Hang, Z., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.047 · Cited by 20
Oatp1a4 and an L-Thyroxine-Sensitive Transporter Mediate the Mouse Blood-Brain Barrier Transport of Amyloid-β Peptide
Minh, T. N., Bedussi, B., Chasseigneaux, S., Dodacki, A., Yapo, C., Chacun, H., Scherrmann, J., Farinotti, R., & Bourasset, F. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121891 · Cited by 22
Glutathione depletion upregulates P-glycoprotein expression at the blood-brain barrier in rats
Wu, J., Hong, H., Ji, H., Wang, Y. Y., Wang, Y., Li, Y. Q., Li, W. G., Long, Y., & Xia, Y. Z. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.06.0016 · Cited by 20
ABCB1 C3435T Polymorphism Influences the Risk for Alzheimer’s Disease
Fehér, Á., Juhász, A., Pákáski, M., Kálmán, J., & Janka, Z. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0427-z · Cited by 20
Transcriptomic Analysis of Rat Cerebral Cortex Reveals the Potential Mechanism of Electroacupuncture Opening Blood Brain Barrier
Ma, C., Gan, L., Wang, H., Ren, L., Lin, Y., Zhao, Y., Zhang, S., Gong, P., & Lin, X. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.834683 · Cited by 17
Implication of ABC transporters in non-proliferative diseases
Grigoreva, T. A., Sagaidak, A. V., Novikova, D., & Tribulovich, V. G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175327 · Cited by 18
Pilocarpine-Induced Convulsive Activity Is Limited by Multidrug Transporters at the Rodent Blood-Brain Barrier
Römermann, K., Bankstahl, J. P., Löscher, W., & Bankstahl, M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221952 · Cited by 20
Recent Progress in Blood–Brain Barrier and Blood–CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain
Tachikawa, M., Uchida, Y., Ohtsuki, S., & Terasaki, T. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_2 · Cited by 19
Somatostatin Maintains Permeability and Integrity of Blood-Brain Barrier in β-Amyloid Induced Toxicity
Paik, S., Somvanshi, R. K., & Kumar, U. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1045-5 · Cited by 20
Synthesis and P-glycoprotein induction activity of colupulone analogs
Bharate, J. B., Batarseh, Y. S., Wani, A., Sharma, S., Vishwakarma, R. A., Kaddoumi, A., Kumar, A., & Bharate, S. B. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00554j · Cited by 20
Is P-glycoprotein Involved in Amyloid-β Elimination Across the Blood–Brain Barrier in Alzheimer’s Disease?
Ohtsuki, S., Ito, S., & Terasaki, T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.160 · Cited by 19
Alzheimer therapeutics—what after the cholinesterase inhibitors?
Walker, L. C., & Rosen, R. F. (2006) · Age and Ageing · doi:10.1093/ageing/afl009 · Cited by 19
Paclitaxel C-10 carbamates: Potential candidates for the treatment of neurodegenerative tauopathies
Ballatore, C., Hyde, E. G., Deiches, R. F., Lee, V. M. ‐., Trojanowski, J. Q., Huryn, D. M., & Smith, A. B. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.058 · Cited by 19
Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
Ni, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18
PLCγ2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer’s disease
Li, K., Ran, B., Wang, Y., Liu, L., & Li, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999061 · Cited by 18
Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET
Mossel, P., Arif, W. M., de Souza, G. S., García-Varela, L., van der Weijden, C. W. J., Boersma, H. H., Willemsen, A. T. M., Boellaard, R., Elsinga, P. H., Borra, R., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06363-5 · Cited by 21
Generation and characterization of a zebrafish knockout model of abcb4, a homolog of the human multidrug efflux transporter P-glycoprotein
Park, J., Kim, H., Alabdalla, L., Mishra, S., & Mchaourab, H. S. (2023) · Human Genomics · doi:10.1186/s40246-023-00530-3 · Cited by 18
Drug Transporters At Brain Barriers
Ashraf, T., Kis, O., Banerjee, N., & Bendayan, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4711-5_2 · Cited by 18
Aβ1-17 is a Major Amyloid-β Fragment Isoform in Cerebrospinal Fluid and Blood with Possible Diagnostic Value in Alzheimer's Disease
Pérez‐Grijalba, V., Pesini, P., Allué, J. A., Sarasa, L., Montañés, M., Lacosta, A.-M., Casabona, D., José, I. S., Boada, M., Tárraga, L., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140156 · Cited by 20
Mouse models of neurological disorders: A view from the blood–brain barrier
Banks, W. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.011 · Cited by 22
Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians
Vendelbo, J. H., Olesen, R. H., Lauridsen, J. K., Rungby, J., Kleinman, J. E., Hyde, T. M., & Larsen, A. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.74 · Cited by 18
Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells
McInerney, M. P., Volitakis, I., Bush, A. I., Banks, W. A., Short, J. L., & Nicolazzo, J. A. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2377-6 · Cited by 18
Effect of mouse strain as a background for Alzheimer’s disease models on the clearance of amyloid-β
Qosa, H., & Kaddoumi, A. (2016) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000123 · Cited by 20
Mapping the Brain’s Glymphatic System
Voumvourakis, K. I., Thomaidis, N. S., & Tsiodras, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020409 · Cited by 17
Preservation of transendothelial glucose transporter 1 and P-glycoprotein transporters in a cortical slice culture model of the blood–brain barrier
Camenzind, R. S., Chip, S., Gutmann, H., Kapfhammer, J. P., Nitsch, C., & Bendfeldt, K. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.073 · Cited by 17
Transport of Drugs Across the blood–brain Barrier in Alzheimer‘s Disease
Nicolazzo, J. A., & Mehta, D. C. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.41 · Cited by 19
Mechanism of anti-AD action of OAB-14 by enhancing the function of glymphatic system
Zhang, X., Cao, R., Zhu, C., Yang, L., Zheng, N., Ji, W., Liu, P., Chi, T., Ji, X., Zheng, Z., et al. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105633 · Cited by 15
Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice
Pyun, J., Koay, H., Runwal, P., Mawal, C., Bush, A. I., Pan, Y., Donnelly, P. S., Short, J. L., & Nicolazzo, J. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082084 · Cited by 16
ABCB1 transporter and Toll-like receptor 4 in trabecular meshwork cells.
Grybauskas, A., Koga, T., Kuprys, P. V., Nolan, M. J., McCarty, R. D., Walker, L., Green, K. A., Norkett, W. M., Yue, B. Y. J. T., & Knepper, P. A. (2015) · Europe PMC (PubMed Central) · Cited by 16
Evidence against a role of P-glycoprotein in the clearance of the Alzheimer’s disease Aβ1–42 peptides
Bello, I., & Salerno, M. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-014-0566-8 · Cited by 18
P-Glycoprotein Altered Expression in Alzheimer's Disease: Regional Anatomic Variability
Jeynes, B., & Provias, J. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/257953 · Cited by 17
The expression of LDL receptor in vessels with blood–brain barrier impairment in a stroke-prone hypertensive model
Ueno, M., Wu, B., Nakagawa, T., Nagai, Y., Onodera, M., Huang, C., Kusaka, T., Kanenishi, K., & Sakamoto, H. (2010) · Histochemistry and Cell Biology · doi:10.1007/s00418-010-0705-y · Cited by 17
Elucidation of mechanism of blood-brain barrier damage for prevention and treatment of vascular dementia
Ueno, M. (2017) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001004 · Cited by 15
Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy
Couyoupetrou, M., Gantner, M. E., Ianni, M. E. D., Palestro, P. H., Enrique, A., Gavernet, L., Ruiz, M. E., Pesce, G. O., Bruno‐Blanch, L. E., & Talevi, A. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666161013103408 · Cited by 16
Syndapin-2 mediated transcytosis of amyloid-β across the blood–brain barrier
Leite, D. M., Seifi, M., Ruiz‐Pérez, L., Nguemo, F., Plomann, M., Swinny, J. D., & Battaglia, G. (2022) · Brain Communications · doi:10.1093/braincomms/fcac039 · Cited by 16
Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases
Bhosale, A., Paul, G., Mazahir, F., & Yadav, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100111 · Cited by 15
Extracellular matrix proteins in construction and function of in vitro blood-brain barrier models
Du, F., Shusta, E. V., & Palecek, S. P. (2023) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2023.1130127 · Cited by 17
Imaging transporters: Transforming diagnostic and therapeutic development
Mann, A., Han, H., & Eyal, S. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.416 · Cited by 15
Regulation of P-glycoprotein by miR-27a-3p at the Brain Endothelial Barrier
Hammad, S., Mabondzo, A. M., Hamoudi, R., & Harati, R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.021 · Cited by 15
Nanotherapeutic Strategies for the Treatment of Alzheimer's Disease
Gu, X. Q., Chen, H., & Gao, X. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.97 · Cited by 15
ABCB1 Genotype and CSF β-Amyloid in Alzheimer Disease
Kohen, R., Shofer, J. B., Korvatska, O., Petrie, E. C., Wang, L. Y., Schellenberg, G. D., Peskind, E. R., & Wilkinson, C. W. (2011) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988711402325 · Cited by 16
ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients.
Frankfort, S. V., Doodeman, V. D., Bakker, R., Tulner, L. R., van Campen, J. P., Smits, P. H. M., & Beijnen, J. H. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-13 · Cited by 15
Therapeutic drugs modulate ATP-Binding cassette transporter-mediated transport of amyloid beta(1–42) in brain microvascular endothelial cells
Shubbar, M. H., & Penny, J. I. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173009 · Cited by 14
The relationship among amyloid-β deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer’s disease pathological process
Yang, Q., Xing, Z., Du, L., Fang, X., Liang, H., Zhang, S., Shi, L., Kuang, C., & Han, T.-X. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.358607 · Cited by 15
New findings concerning vertebrate porin II — On the relevance of glycine motifs of type-1 VDAC
THINNES, F. P. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.01.008 · Cited by 14
Granisetron Alleviates Alzheimer’s Disease Pathology in TgSwDI Mice Through Calmodulin-Dependent Protein Kinase II/cAMP-Response Element Binding Protein Pathway
Rihani, S. B. A., Lan, R. S.-L., & Kaddoumi, A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190849 · Cited by 14
Role of A β Transport and Clearance in the Pathogenesis and Treatment of Alzheimer’s Disease
Holtzman, D. M., & Zloković, B. V. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_11 · Cited by 15
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Central integration mechanisms of neurovascular unit dysfunction and novel synergistic therapeutic strategies
Wang, H., Qiao, Y., Lu, H., Bo, X., Chen, F., Pu, N., Zhou, Y., & Cheng, Q. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107224 · Cited by 13
Plant extracts as emerging modulators of neuroinflammation and immune receptors in Alzheimer's pathogenesis
mohamed, I. E., Osman, E. E., Saeed, A. M., Ming, L. C., Goh, K. W., Razi, P., Abdullah, A. D. I., & Dahab, M. M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35943 · Cited by 16
Increased Efflux of Amyloid-β Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis
Paganetti, P., Antoniello, K., Devraj, K., Toni, N., Kieran, D., Madani, R., Pihlgren, M., Adolfsson, O., Froestl, W., Schrattenholz, A. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131091 · Cited by 13
Self-citation
Behavioural Consequences of P‐Glycoprotein Deficiency in Mice, with Special Focus on Stress‐Related Mechanisms
Schoenfelder, Y., Hiemke, C., & Schmitt, U. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02278.x · Cited by 14
A Benzopyrane Derivative as a P‐Glycoprotein Stimulator: A Potential Agent to Decrease β‐Amyloid Accumulation in Alzheimer’s Disease
Contino, M., Cantore, M., Capparelli, E., Perrone, M. G., Niso, M., Inglese, C., Berardi, F., Leopoldo, M., Perrone, R., & Colabufo, N. A. (2011) · ChemMedChem · doi:10.1002/cmdc.201100469 · Cited by 13
Drug Transport in the Brain
Ashraf, T., Ronaldson, P. T., & Bendayan, R. (2014) · doi:10.1002/9781118705308.ch14 · Cited by 13
Age-related decline in blood-brain barrier function is more pronounced in males than females in parietal and temporal regionsPreprint
Shao, X., Shou, Q., Felix, K., Ojogho, B., Jiang, X., Gold, B. T., Herting, M. M., Goldwaser, E. L., Kochunov, P. V., Hong, E. L., et al. (2024) · eLife · doi:10.7554/elife.96155 · Cited by 13
Data-independent acquisition proteomic analysis of the brain microvasculature in Alzheimer’s disease identifies major pathways of dysfunction and upregulation of cytoprotective responses
Erickson, M. A., Johnson, R. S., Damodarasamy, M., MacCoss, M. J., Keene, C. D., Banks, W. A., & Reed, M. J. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00581-1 · Cited by 12
Hyperhomocysteinemic Mice Show Cognitive Impairment Without Features of Alzheimer's Disease Phenotype
Rhodehouse, B. C., Erickson, M. A., Banks, W. A., & Bearden, S. E. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122347 · Cited by 12
Susceptibility to Focal and Global Brain Ischemia of Alzheimer Mice Displaying Aβ Deposits: Effect of Immunoglobulin
Heikkinen, R., Malm, T., Heikkilä, J., Muona, A., Tanila, H., Koistinaho, M., & Koıstınaho, J. (2014) · Aging and Disease · doi:10.14336/ad.2014.050076 · Cited by 12
Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells
Newman, S. A., Pan, Y., Short, J. L., & Nicolazzo, J. A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03006-y · Cited by 13
Mamma Mia, P‐glycoprotein binds again
Callaghan, R., Gelissen, I. C., George, A. M., & Hartz, A. M. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.13951 · Cited by 12
The Function and Expression of ATP-Binding Cassette Transporters Proteins in the Alzheimer's Disease
Aykaç, A., & Sehirli, A. Ö. (2021) · Global Medical Genetics · doi:10.1055/s-0041-1735541 · Cited by 12
Neurodegeneration Caused by Polyglutamine Expansion Is Regulated by P-Glycoprotein in Drosophila melanogaster
Yadav, S., & Tapadia, M. G. (2013) · Genetics · doi:10.1534/genetics.113.155077 · Cited by 12
In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice
Yasuda, K., Cline, C., Lin, Y. S., Scheib, R., Ganguly, S., Thirumaran, R. K., Chaudhry, A. S., Kim, R. B., & Schuetz, E. G. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065078 · Cited by 12
Decreased blood–brain Barrier Expression of P-glycoprotein in Alzheimer‘s Disease: Impact on Pathogenesis and Brain Access of Therapeutic Agents
Nicolazzo, J. A., & Banks, W. A. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.65 · Cited by 11
Why cancer survivors have a lower risk of Alzheimer disease
THINNES, F. P. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.06.016 · Cited by 11
Common and Rare Genetic Variants Associated With Alzheimer's Disease
Marei, H. E. S., Thani, A. A. A., Suhonen, J., Zowalaty, M. E. E., Al-Banna, M. A., Cenciarelli, C., Wang, T., & Caceci, T. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25225 · Cited by 11
Natural Products based P-glycoprotein Activators for Improved β-amyloid Clearance in Alzheimer’s Disease: An in silico Approach
Shinde, P., Vidyasagar, N., Dhulap, S., Dhulap, A., & Hirwani, R. R. (2015) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524915666150826092152 · Cited by 11
Role of ABC transporters in the pathology of Alzheimer’s disease
Zhao, Y., Hou, D., Feng, X., Lin, F., & Luo, J. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0060 · Cited by 11
Multidrug Resistance P-Glycoprotein (P-gp), Glucocorticoids, and the Stress Response
Bloise, E., & Matthews, S. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813146-6.00019-9 · Cited by 11
In situ blood–brain barrier permeability of a C-10 paclitaxel carbamate
Ballatore, C., Zhang, B., Trojanowski, J. Q., Lee, V. M. ‐., & Smith, A. B. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.024 · Cited by 11
Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS)
Frankfort, S. V., van Campen, J., Tulner, L. R., & Beijnen, J. H. (2008) · Current Clinical Pharmacology · doi:10.2174/157488408785747665 · Cited by 11
Assessing the Impact of Lithium Chloride on the Expression of P-Glycoprotein at the Blood-Brain Barrier
Newman, S. A., Pan, Y., Short, J. L., & Nicolazzo, J. A. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.01.013 · Cited by 11
The Cerebral Microcirculation
Tuma, R. F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374530-9.00013-9 · Cited by 11
Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration
Bartels, A. L., Kortekaas, R., & Leenders, K. L. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.140 · Cited by 11
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 11
P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities
Asante, J., & Barger, S. W. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2495632 · Cited by 11
Vascular models of Alzheimer's disease: An overview of recent in vitro models of the blood-brain barrier
Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 11
Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model
Wanek, T., Zoufal, V., Brackhan, M., Krohn, M., Mairinger, S., Filip, T., Sauberer, M., Stanek, J., Pekar, T., Pahnke, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218245 · Cited by 9
The Cerebral Microcirculation
Tuma, R. F. (2008) · Comprehensive physiology · doi:10.1002/cphy.cp020411 · Cited by 9
Fiscalin Derivatives as Potential Neuroprotective Agents
Barreiro, S., Silva, B., Long, S., Pinto, M. M. M., Remião, F., Sousa, E., & Silva, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071456 · Cited by 9
Alzheimer's disease brain endothelial-like cells reveal differential drug transporter expression and modulation by potentially therapeutic focused ultrasound
Chaves, J. C. S., Wasielewska, J. M., Cuní‐López, C., Rantanen, L. M., Lee, S., Koıstınaho, J., White, A. R., & Oikari, L. E. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.009 · Cited by 10
Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies
Bonada, M., Pittarello, M., Fazio, E. D., Gans, A., Alimonti, P., Slika, H., Legnani, F. G., Meco, F. D., & Tyler, B. (2024) · Genes · doi:10.3390/genes15081038 · Cited by 10
The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat
Tai, L. M., Jacobsen, H., Ozmen, L., Flohr, A., Jakob‐Roetne, R., Caruso, A., & Grimm, H. P. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9246-4 · Cited by 9
11C‐ and 18F‐Labeled Radioligands for P‐Glycoprotein Imaging by Positron Emission Tomography
Cantore, M., Benadiba, M., Elsinga, P. H., Kwizera, C., Dierckx, R., Colabufo, N. A., & Luurtsema, G. (2015) · ChemMedChem · doi:10.1002/cmdc.201500420 · Cited by 9
Glucocorticoids modify effects of TGF-β1 on multidrug resistance in the fetal blood-brain barrier
Baello, S., Iqbal, M., Kearney, S., Kuthiala, S., Bloise, E., Gibb, W., & Matthews, S. G. (2016) · Growth Factors · doi:10.3109/08977194.2016.1162163 · Cited by 9
Plasma amyloid beta level changes in aged mice with cognitive dysfunction following sevoflurane exposure
Liang, R., Ou, S., Han, Y., Xu, J., & Zhou, S. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110737 · Cited by 9
Targeted Chemotherapy in Drug-Resistant Tumors, Noninvasive Imaging of P-Glycoprotein-Mediated Functional Transport in Cancer, and Emerging Role of Pgp in Neurodegenerative Diseases
Sivapackiam, J., Gammon, S. T., Harpstrite, S. E., & Sharma, V. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_8 · Cited by 9
Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood–brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies
Elfakhri, K. H., Duong, Q.-V., Langley, C., Depaula, A., Mousa, Y. M., Lebeouf, T., Cain, C. M., & Kaddoumi, A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.028 · Cited by 9
Deactivation of ATP-Binding Cassette Transporters ABCB1 and ABCC1 Does Not Influence Post-ischemic Neurological Deficits, Secondary Neurodegeneration and Neurogenesis, but Induces Subtle Microglial Morphological Changes
Manrique‐Castano, D., Sardari, M., de Carvalho, T. S., Doeppner, T. R., Popa‐Wagner, A., Kleinschnitz, C., Chan, A., & Hermann, D. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00412 · Cited by 9
Human isogenic cells of the neurovascular unit exert transcriptomic cell type-specific effects on a blood-brain barrier in vitro model of late-onset Alzheimer disease
Haferkamp, U., Hartmann, C., Abid, C. L., Brachner, A., Höchner, A., Gerhartl, A., Harwardt, B., Leckzik, S., Leu, J., Metzger, M., et al. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00471-y · Cited by 12
[11C]Metoclopramide PET can detect a seizure-induced up-regulation of cerebral P-glycoprotein in epilepsy patients
Biali, M. E., Breuil, L., Jackwerth, M., Mairinger, S., Weber, M., Wölfl‐Duchek, M., Bamminger, K., Rausch, I., Nics, L., Hacker, M., et al. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00588-8 · Cited by 8
Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice
Peng, H., Bukuroshi, P., Durk, M. R., Grootendorst, P. V., Yan, X., Pan, S. R., de Lannoy, I. A. M., & Pang, K. S. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2297 · Cited by 8
Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice
Endres, K., Reinhardt, S., Geladaris, A., Knies, J., Grimm, M. O. W., Hartmann, T., & Schmitt, U. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0280-9 · Cited by 9
A Combination of Clioquinol, Zinc and Copper Increases the Abundance and Function of Breast Cancer Resistance Protein in Human Brain Microvascular Endothelial Cells
Yap, C., Short, J. L., & Nicolazzo, J. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.04.010 · Cited by 8
Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview
Lau, L., & Brodney, M. A. (2007) · Springer eBooks · doi:10.1007/7355_2007_017 · Cited by 8
Management of Epilepsy - Research, Results and Treatment
Günel, M. K. (2011) · InTech eBooks · doi:10.5772/1139 · Cited by 8

Authors: Cirrito, J. R.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Cirrito, J. R.
ORCID: Cirrito, J. R.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2005-11-01
Volume: 115
Issue: 11
Pages: 3285-3290
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci25247
PMC: PMC1257538
OpenAlex: W2163209521
Cited by: 660
References: 34
Citations by year: 2026: 21 · 2025: 24 · 2024: 29 · 2023: 36 · 2022: 31 · 2021: 30 · 2020: 37 · 2019: 31 · 2018: 30 · 2017: 35 · 2016: 43 · 2015: 40 · 2014: 41 · 2013: 44 · 2012: 26
FWCI: 12.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: U.S. Department of Energy
National Institutes of Health (CA94056, AG13956)
National Institute on Aging (AG023316, R03AG023316, R01AG023084, AG23084, R01AG013956, R37AG023084, R37AG013956)
National Cancer Institute (P50 CA94056, P50CA094056)
National Institute of Allergy and Infectious Diseases (AI-13956)
National Institute of Neurological Disorders and Stroke (NS034467, R37NS034467, R01NS034467)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords: P-glycoprotein, blood-brain barrier, amyloid-beta, Alzheimer's disease, APP transgenic mice, P-glycoprotein inhibitors, brain interstitial fluid, amyloid-beta clearance, brain microvascular endothelial cells, amyloid-beta deposition
MeSH terms: Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Mice, Inbred C57BL, Mice, Transgenic, Polymorphism, Genetic, Up-Regulation, Amyloid beta-Peptides, Mice, Knockout, ATP Binding Cassette Transporter, Subfamily B, Member 1, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer disease mouse model

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks